# ENSYSCE BIOSCIENCES, INC. (ENSC) · Edgar & Edgarette company card

> Ensysce Biosciences (ENSC) saw revenue fall 2.8% in FY2025 to $5 million, operating margin -202% against a -3.8% median for pharmaceutical preparations, equity 43.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1716947 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ENSC) · [JSON](https://www.pops4.com/boards/company/ENSC.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $5M |
| Revenue growth, 1 year | -2.8% |
| Revenue growth per year | 9.4% |
| Operating margin | -202.1% (prior year -129.2%) |
| Net margin | -200.8% |
| Operating cash flow | −$8M |
| Capital spending | $123,643 |
| Free cash flow | −$8M |
| Cash | $4M |
| Long-term debt | — |
| Total assets | $7M |
| Total equity | $3M |
| Equity ÷ assets | 43.1% |
| Return on equity | -316.6% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -67.26 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -202.1% in FY2025; revenue is hard to predict: its 80% range is ±65%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $5.1M (FY2025). Experience: revenue down 2.8% on the year, up 9.4% a year over 4 years; operating margin -202.1%, down from -129.2%. Soundness: equity 43.1% of assets, return on equity -316.6%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $2.6M and $12.2M next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $2.3M to $13.6M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -202.1% against a -3.8% median; growth -2.8% against 13.7%.

Range logged 2026-09-30, receipt dfd15b9a0f1e28a1, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-05-22 ([filing](https://www.sec.gov/Archives/edgar/data/1716947/000149315226025061/0001493152-26-025061-index.htm))
- Item 5.02 Director or officer change: 5, latest 2026-11-04 ([filing](https://www.sec.gov/Archives/edgar/data/1716947/000149315226049906/0001493152-26-049906-index.htm))

## Recent filings

- 10-Q · filed 2026-11-12 · [filing](https://www.sec.gov/Archives/edgar/data/1716947/000149315226051422/0001493152-26-051422-index.htm)
- 8-K · filed 2026-11-12 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1716947/000149315226051414/0001493152-26-051414-index.htm)
- DEF 14A · filed 2026-11-12 · [filing](https://www.sec.gov/Archives/edgar/data/1716947/000149315226051410/0001493152-26-051410-index.htm)
- 8-K · filed 2026-11-04 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1716947/000149315226049906/0001493152-26-049906-index.htm)
- 8-K · filed 2026-09-29 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1716947/000149315226044802/0001493152-26-044802-index.htm)
- 8-K · filed 2026-08-25 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1716947/000149315226040080/0001493152-26-040080-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001716947.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1716947

## Cite

POPS4, Edgar & Edgarette: ENSYSCE BIOSCIENCES, INC. (ENSC) company card, from the company's own SEC filings, accessed 2026-11-14, https://www.pops4.com/boards/company/ENSC. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.